Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
FATE•RECLAIM-LN trial begins for FT819 in lupus nephritis
Aug. 14 (Reuters) - Fate Therapeutics Inc. FATE.O:
- Fate Therapeutics initiates potentially registrational RECLAIM-LN clinical trial of FT819 for the treatment of lupus nephritis
- Patients to receive single 900 million-cell dose of FT819; primary endpoint at week 26
Source text: ID:nGNX3VKK1W
Further company coverage: FATE.O
